Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
How do you approach renal cell carcinoma with ipsilateral vs contralateral adrenal metastasis? Is there a role of surgery?
Related Questions
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
How do you manage anemia associated with belzutifan therapy?
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
How do you manage hypoxia induced by belzutifan?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
What are your top takeaways from ASCO GU 2025?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
